
US Marshals Seize Unapproved Drug From Crescendo Therapeutics
Federal marshals seized an unapproved topical corticosteroid medication from California-based Crescendo Therapeutics.
Federal marshals seized an unapproved topical corticosteroid medication from California-based Crescendo Therapeutics. The medication, HybriSil (methylprednisolone acetate 1% percent in silicone gel) was marketed for the treatment of scars and skin disorders, an indication for which it did not have FDA approval.
The seizure follows two FDA inspections of Crescendo Therapeutics. After an April 2011 inspection, FDA cited the company in a
According to the FDA
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.